Our results indicated that ERG protein expression may be useful for molecularly subtyping prostate cancer and prostate needle biopsy evaluation (Park et?al., 2010). both TMPRSS2\ERG positive cell lines and tissues, but not in cell lines or tissues lacking the TMPRSS2\ERG rearrangement, clearly indicating that ERG protein expression is significantly increased in the presence of the TMPRSS2\ERG gene fusion. Significantly, our results provide evidence that two distinct ERG protein isoforms are simultaneously expressed in TMPRSS2\ERG positive samples as evidenced by the concomitant detection of two mutually exclusive peptides in two patient tumors and in the VCaP prostate cancer cell line. Three peptides, shared across almost all fusion protein products, were determined to be the most abundant peptides, providing signature peptides for detection of ERG over\expression resulting from TMPRSS2\ERG gene fusion. The PRISM\SRM assays provide valuable tools for studying TMPRSS2\ERG gene fusion protein products in prostate cancer. and a dwell time of 10?ms were used. A large fraction of the capillary column eluent flowing at a rate of 3?L/min was automatically collected every 1?min into a 96\well plate using a Triversa NanoMate? system A 839977 (Advion BioSciences, Ithaca, NY) over the course of 100?min LC separation. Prior to peptide fraction collection, 17?L of water was added to each well in the plate to avoid peptide loss and also to dilute the peptide fraction for LC\SRM analysis. The fraction containing a target peptide was intelligently selected based on the retention time of the peptide obtained by on\line monitoring. The detailed method for intelligent selection was described in our previous study (Shi et?al., 2012). 2.5. LC\SRM analysis Following high pH capillary RPLC separation and intelligent selection, the fractions containing the target peptides were subjected to LC\SRM analysis. All peptide fractions were analyzed using a nanoACQUITY UPLC? system coupled on\line to a TSQ Vantage triple quadrupole mass spectrometer. The UPLC? system was equipped with an ACQUITY UPLC BEH 1.7?m C18 column (75?m i.d.??25?cm), which was connected to a chemically etched 20?m i.d. fused\silica emitter via a Valco stainless steel union. Four microliters of each peptide fraction were loaded onto the column at a flow rate of 1 1?L/min for 5?min. Peptides were separated at a flow rate of 500?nL/min using a 10?min linear gradient from 5 to 65% acetonitrile in water. The TSQ Vantage was operated in the same A 839977 manner as the TSQ Quantum Ultra. 2.6. Calibration curve experiments Tryptic peptides from four TMPRSS2\ERG negative tissue samples were pooled and used as the matrix for the calibration curve experiments. Heavy standard peptides were spiked into the matrix at a constant concentration of 5?fmol/L, while light peptides (purity 97%) were spiked at 0, 0.5, 1, 2, 5, 10, 20, 50, 100 and 500?amol/L levels. The concentration of peptide mixture in each individual data point was adjusted to 1 1?g/L. All spike\in samples were analyzed using the same PRISM\SRM method used for analysis of prostate cancer cell line and tumor tissue samples as mentioned above. Light to heavy peak area ratios were plotted against the corresponding light peptide concentration values to build a calibration curve for each peptide. The limit of detection (LOD) and limit of quantification (LOQ) were defined as the lowest concentration point of target peptides at which the S/N of surrogate peptides was at least 3 and 10, respectively. Signal to noise ratio (S/N) was calculated by the peak apex intensity over the highest background noise in a retention time region of 10?s for the target peptides. 2.7. Data analysis The raw data acquired on the TSQ Vantage triple quadrupole MS were initially imported into Skyline software (MacLean et?al., 2010) for visualization of chromatograms of target peptides and to determine which peptides can be detected. The A 839977 detected peptides were further quantified using Xcalibur 2.0.7 (Thermo Fisher Scientific). The most abundant transition for each peptide was used for quantification unless interference was observed. Peak detection and integration were based on two criteria: 1) the same retention time and 2) approximately the same Mouse monoclonal to BID relative peak intensity ratios across multiple transitions between light peptide and heavy peptide standards. All data were manually inspected to ensure correct peak detection and accurate integration. Light to heavy peak area ratios were used to quantify target peptides. The expression level of each peptide in cell line or tissue samples (amol/g of total protein) was calculated by the A 839977 following equation: (amol/L concentration of endogenous target peptide calculated based on calibration curve)??(L loading volume on\column)/(g loading amount on\column). Extracted ion chromatograms (XICs) were created using Skyline. 3.?Results 3.1. Study design The goal of this study was to accurately detect and quantify TMPRSS\ERG fusion products in prostate cancer at the protein level. To achieve this goal, we have applied an antibody\independent PRISM\SRM method. Briefly, a list of peptides that uniquely represent ERG A 839977 protein were selected and synthesized for development of SRM assays, and.